Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 48Neoplasms 43Depression 31Fatigue 30Prostatic Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, Follicular 18Lymphoma, Large B-Cell, Diffuse 17Multiple Myeloma 16Carcinoma, Non-Small-Cell Lung 16Lymphoma, Non-Hodgkin 15Lung Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Mantle-Cell 14Leukemia, Myeloid, Acute 14Hodgkin Disease 14Colorectal Neoplasms 14Burkitt Lymphoma 14Anxiety Disorders 14Pain 13Lymphoma, B-Cell, Marginal Zone 13Lymphoma, Large-Cell, Immunoblastic 12Lymphoma 11Leukemia, Myeloid, Chronic-Phase 11Head and Neck Neoplasms 11Blast Crisis 11Lymphoma, T-Cell, Cutaneous 10Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 10Leukemia, Myeloid, Accelerated Phase 10Leukemia, Hairy Cell 10

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioma × Therapeutics × Clear all
NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

Massachusetts General Hospital

Phase EARLY_PHASE1 Active not recruiting
16 enrolled
CNS

Glioma

NCT06305910 2024-03-12

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

OX2 Therapeutics

Phase 1 Recruiting
24 enrolled
CNS

Glioma

NCT00360828 2017-03-23

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
10 enrolled 6 charts
CNS

Astrocytoma, Brain Neoplasms, Glioma, Neurologic Manifestations, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡